Pages that link to "Q39999171"

The following pages link to A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor (Q39999171):

Displaying 15 items.

• Structure-based Engineering of Species Selectivity in the Interaction between Urokinase and Its Receptor: IMPLICATION FOR PRECLINICAL CANCER THERAPY (Q27659603) (← links)
• Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion. (Q33709060) (← links)
• Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding. (Q34370103) (← links)
• A deficiency of uPAR alters endothelial angiogenic function and cell morphology (Q35019176) (← links)
• The non-phagocytic route of collagen uptake: a distinct degradation pathway (Q35128318) (← links)
• Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction. (Q35312973) (← links)
• A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction (Q35559411) (← links)
• Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor. (Q35604600) (← links)
• Vitronectin inhibits efferocytosis through interactions with apoptotic cells as well as with macrophages (Q36625153) (← links)
• Regulation of cell signalling by uPAR. (Q37660895) (← links)
• Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist (Q38120755) (← links)
• Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells (Q39128849) (← links)
• Urinary-type plasminogen activator receptor (uPAR) modulates oral cancer cell behavior with alteration in p130cas. (Q39532629) (← links)
• Urokinase-type plasminogen activator inhibits efferocytosis of neutrophils (Q41973656) (← links)
• Vitronectin and Urokinase-Type Plasminogen Activator Gene Expression Levels Are Increased in Patients with Coronary Artery In-Stent Restenosis (Q49984918) (← links)